Image: Tumour Heterogeneity The NHS in UK has finally approved Kadcyla, Roche Pharmaceuticals breast cancer drug, for routine use after a four-year campaign. The drug extends the lives of women with advanced forms of breast cancer by some six months. It was hitherto only available on a case-by-case basis through the Cancer Drugs Fund because…
Tagrisso, (Osimertinib), a last-chance drug produced by AstraZeneca that can lead to an “unprecedented” reduction in lung cancer tumours is now available on the NHS thanks to the newly updated Cancer Drugs Fund rules which allow a promising drug to be used while still in trial evaluation. The once-a-day tablet will be available immediately for…
24 November. A Big Day for the re-opening of the Piam Brown pediatric oncology Ward at Southampton Hospital by the Duchess of Cornwall. Caring Cancer Trust Chairman Chris Ody, together with charity shop volunteers Ian and Amy MacWatt and Gerry Bradley, took a moment for a photo with Piam Brown Charity Coordinator Rachel Funnell in…
There is good news this week for the 1,400 women a year who suffer from the aggressive HER2-positive breast cancer. Nice have now approved the use of the drug Perjeta, (the Roche brand name for pertuzumab), following the pharma manufacturer’s agreement to drop the price for NHS use. The drug Perjeta is used in combination…